Excess mortality in adults with documented diabetes in Germany: routine data analysis of all insurance claims in Germany 2013–2014 by Schmidt, Christian et al.
1Schmidt C, et al. BMJ Open 2021;11:e041508. doi:10.1136/bmjopen-2020-041508
Open access 
Excess mortality in adults with 
documented diabetes in Germany: 
routine data analysis of all insurance 
claims in Germany 2013–2014
Christian Schmidt   , Lukas Reitzle, Christin Heidemann   , Rebecca Paprott   , 
Thomas Ziese, Christa Scheidt- Nave, Jens Baumert   
To cite: Schmidt C, 
Reitzle L, Heidemann C, 
et al.  Excess mortality in 
adults with documented 
diabetes in Germany: 
routine data analysis of all 
insurance claims in Germany 
2013–2014. BMJ Open 
2021;11:e041508. doi:10.1136/
bmjopen-2020-041508
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
041508).
Received 10 June 2020
Revised 16 December 2020
Accepted 17 December 2020
Department of Epidemiology and 
Health Monitoring, Robert Koch 
Institute, Berlin, Germany
Correspondence to
Dr Christian Schmidt;  
 schmidtchri@ rki. de
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objectives Little is known about the age- specific excess 
mortality pattern of people with diagnosed diabetes in 
Germany. Thus, our goal was to determine the excess 
mortality in diagnosed diabetes overall and stratified by 
age and sex based on claims data.
Design Routine data analysis using a claims dataset from 
all statutory health- insured persons in Germany in 2013, 
which accounts for about 90% of the population.
Participants We included persons who lived in Germany, 
were insured at least 360 days, were not self- paying any 
health services and were aged 30 years or older leading 
to a total number of 47.3 million insured persons for 
analyses.
Exposure Diabetes was determined by the International 
Classification of Diseases-10 codes E10–E14, which 
were documented in 2013 in at least two- quarters on an 
outpatient setting or at least once on an inpatient setting.
Outcome measures The vital status in the study 
population was drawn from the claims dataset for the year 
2014. We derived the excess mortality estimated as an 
age- adjusted mortality rate ratio (MRR) by sex and for age 
groups using a Poisson model.
Main results We found age- adjusted MRRs (95% CI) for 
diabetes of 1.52 (1.51 to 1.52) for women and 1.56 (1.56 
to 1.56) for men. These figures declined with increasing 
age and were highest for ages 30–34 years with 6.76 
(4.99 to 9.15) for women and 6.87 (5.46 to 8.64) for men, 
and lowest for age 95 years and older with 1.13 (1.10 to 
1.15) for women and 1.11 (1.05 to 1.17) for men.
Conclusions We derived deeply age- stratified figures on 
excess mortality in diabetes for Germany. Establishing a 
sustainable analysis of excess mortality is aimed at within 
the framework of diabetes surveillance.
INTRODUCTION
Diabetes mellitus is a chronic metabolic disease 
of high public health impact in Germany and 
worldwide.1 According to the Global Burden 
of Disease Study 2017, diabetes ranks among 
the top 10 leading causes of death globally.2 
Available treatment with insulin and glucose- 
lowering drugs has greatly reduced the risk of 
acute complications and premature mortality. 
Nevertheless, persons with diabetes still have 
a higher age- adjusted risk of death compared 
with persons without diabetes mainly because 
of an increased risk of microvascular and 
macrovascular complications.3
Monitoring diabetes- related mortality 
over time is an important part of national 
diabetes surveillance activities, as the age- 
specific excess risk of death among persons 
with diabetes compared with those without 
diabetes serves as an indicator of quality 
of diabetes care. Some countries, such as 
Sweden, Denmark and Scotland, have estab-
lished National Diabetes Registers, and along 
with a legal basis for individual health data 
linkage, these data allow a reliable assessment 
of diabetes- related mortality in comparison 
with the general population4 5 or population- 
based controls.6 Results from these coun-
tries consistently demonstrate a significantly 
higher risk of death in association with 
diabetes, but greatly vary with regard to the 
overall magnitude of excess risk as well as sex 
Strengths and limitations of this study
 ► This is the first study in Germany, which analyses 
excess mortality of diabetes on the basis of routine 
data covering almost the entire German population.
 ► The completeness of the study data in terms of 
deaths and documented diagnosis allows calculat-
ing nearly unbiased and deep- stratified diabetes- 
related mortality.
 ► We have not distinguished the type of diabetes be-
cause routine data contain implausible double diag-
noses of type 1 and type 2 diabetes in the same 
person.
 ► The study data are limited to documented diagno-
ses, that is, no information about undiagnosed mor-
bidity is available.
 ► In principle, the study data allow a continuous as-
sessment of changes in mortality, which is suitable 
for public health surveillance.
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differences. A recent meta- analysis of diabetes- related all- 
cause mortality based on 86 prospective cohorts showed 
a higher pooled adjusted relative risk of death among 
women than men (1.93 vs 1.74).7 The studies from Sweden 
as well as a further study from Australia have been age 
disaggregated, indicating that excess mortality among 
persons with type 2 diabetes significantly decreases with 
increasing chronological age.6 8
In Germany, a national diabetes surveillance system is 
currently being established at the Robert Koch Institute as 
the national public health institute. One of the main goals 
is to cover the diabetes- related mortality continuously ( 
www. diabsurv. rki. de). Over the past 20 years, a number of 
epidemiological studies in Germany have provided esti-
mates of mortality rate ratios (MRRs) comparing mortality 
rates among persons with and without diabetes. The 
results from these studies vary due to differences in study 
design and study populations, methodological issues, 
regional versus national data, follow- up time, and insight 
from age- stratified and sex- stratified analyses is limited 
due to the small number of observations.9 In addition to 
these population- based estimates, a recent study estimated 
diabetes- related MRRs for the population 65–90 years of 
age in Germany based on mathematical modelling using 
official death statistics, and prevalence and incidence 
estimates derived from statutory health insurance (SHI) 
claims data.10 Due to partly conflicting findings stated 
above, further research is needed to increase knowledge 
on diabetes- related excess mortality, especially with respect 
to differences in magnitude by age, sex, region and time 
trend.
Information on mortality has recently been added to an 
SHI claims dataset with complete records of all insured 
persons in Germany. As almost 90% of the population is 
covered by SHI, this data source has enormous potential 
for public health research, including detailed analyses of 
mortality patterns. The present study for the first time 
used outpatient and inpatient SHI claims data drawn from 
this dataset to analyse observed mortality rates for adults 
in Germany with and without diagnosed diabetes. Up to 
now, diabetes- related MRRs from the age of 30 years in 
5- year age bands have not been available for the German 
population. Against this background our main aim was 
to provide for the first time estimates of MRRs related to 
diabetes within strata of narrow age bands and sex for 
Germany, and thus add important knowledge in diabetes- 
related excess mortality. Deeply stratified mortality rates 
based on valid data are important for the surveillance 
of diabetes in Germany, as they allow a comparison over 
time and with other countries.
METHODS
Source of data
We used the SHI claims research dataset hosted by the 
German Institute for Medical Documentation and Infor-
mation (DIMDI).11 According to the Data Transparency 
Regulation Act (DaTraV) 2012, this dataset has been 
made accessible to authorised health researchers. Orig-
inally, these data were collected within the scope of the 
German morbidity- based risk- adjustment scheme.12 The 
dataset includes medical data from approximately 70 
million people covered by SHI, which are about 90% 
of the German population. The DaTraV data contain 
complete data on outpatient and inpatient diagnoses 
as well as prescribed drugs and the vital status.11 There-
fore, the data can be analysed across all sectors of care 
and providers within the SHI system. For reasons of data 
protection, there is no direct access to these stored indi-
vidual data. Analyses are limited to aggregate data, which 
can be requested from the DIMDI data processing centre. 
A research question needs to be submitted together with 
an analytical scheme or a syntax query for data analysis. 
The request has to be approved by the data processing 
centre and the aggregated results are checked and trans-
mitted to the applicant.
We developed an SQL script for the analysis of mortality 
rates among persons with and without diabetes based on 
DaTraV datasets 2013 and 2014. As described in detail 
below, the SQL script had to take into account several 
specifics of the data, including assessment of vital status 
and the case definition for diabetes.13
Study population
Information from more than 70 million SHI persons 
was available for the year 2013 (figure 1). In addition 
to the individual SHI identification number, the year of 
birth and sex were checked for unique assignment to 
the insured person. Persons with an insured period of 
less than 360 days, persons who cover at least partly their 
own health expenditure and persons with main residence 
Figure 1 Flow chart of selection of study population with 
excluding criteria and sample sizes.
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abroad were excluded from the analysis, because this may 
have precluded documentation of diabetes within the 
year 2013.
After these exclusions but mainly due to an insurance 
period of less than 360 days, about 65.8 million persons 
were considered eligible for analysis. In addition, persons 
aged younger than 30 years were excluded for data 
protection reasons due to the small number of deaths 
among persons with diabetes in these age groups. The 
final study population hence comprised a total of 47.3 
million persons (figure 1). Of these, 6.5 million persons 
with diabetes fulfilled the case definition for diabetes and 
40.8 million persons were defined as having no diabetes. 
As the flow chart reveals, 0.29 million persons in the 
population with diabetes and 0.48 million persons in the 
population without diabetes died in 2014 (figure 1).
Patient and public involvement
No patient was involved.
Definition of diabetes
We used the International Classification of Diseases (ICD-
10) codes E10–E14 to define diabetes:
 ► E10—type 1 diabetes mellitus.
 ► E11—type 2 diabetes mellitus.
 ► E12—malnutrition- related diabetes mellitus.
 ► E13—other specified diabetes mellitus, for example 
diabetes related to pancreatic insufficiency.
 ► E14—unspecified diabetes mellitus.
In the outpatient setting, documentation of an addi-
tional ICD- tag ‘G’ is required to indicate a confirmed 
diagnosis of diabetes. In the present analysis, this addi-
tional requirement was applied to all data originating in 
the outpatient setting, in order to increase the validity of 
the case definition for diabetes. Furthermore, an outpa-
tient diagnosis of diabetes had to be documented in at 
least two- quarters of the year for validation reasons. This 
definition is related to the m2Q criterion, which was orig-
inally used for reimbursement and is also recommended 
for epidemiological studies.14 In the case of inpatient- 
documented diagnosis, one primary or secondary diag-
nosis of diabetes in the year 2013 was sufficient to identify 
a diabetes case.
In order to examine the impact of potential misclassi-
fication on the results, we conducted sensitivity analyses 
applying modified case definitions for diagnosed diabetes 
based on less stringent criteria: first, documentation of at 
least one confirmed outpatient diagnosis or one inpatient 
diagnosis in 2013 (‘m1Q criterion’), and second, docu-
mentation of only one confirmed outpatient diagnosis in 
2013 without any documented inpatient diagnosis.
Assessment of mortality
We calculated the mortality rates based on the vital status 
in 2014, since in the event of death no diagnoses for the 
year of death are available in the dataset.11 The reason 
for this approach is that the SHI claims dataset was origi-
nally created only for morbidity- adjusted reimbursement 
of SHI companies and diagnoses in the year of death 
were not transmitted. Therefore, we used the difference 
of the year 2014 and the year of birth to calculate the age 
groups.
In order to examine whether assessment of vital status 
in the SHI claims dataset produced plausible results, we 
compared the observed overall mortality rates as total 
counts per 100 000 persons across age groups and strat-
ified by sex with the corresponding mortality rates from 
the official cause of death statistics in Germany for the 
year 2014.15 As illustrated in figure 2 mortality rates per 
100 000 persons based on data from both sources showed 
high consistency in both sexes and in nearly all age 
groups, with only minor deviations among middle- aged 
men and women 85 years of age and older.
Statistical analysis
We estimated age- specific and sex- specific MRRs and 95% 
CIs using Poisson regression. We applied the GENMOD 
procedure implemented in the statistical software SAS 
(V.9.4 for Windows).16 Due to the aggregated count data 
of our study population, we applied a count model for 
MRR estimations. We preferred a Poisson model to a 
log- binomial model or negative binomial model, as the 
Poisson distribution provides a good approximation to 
the underlying binomial distribution due to increasing 
sample size and better convergence properties.16 One 
central assumption of the model is equality of mean and 
variance, which is often not fulfilled for count data. In 
our analyses, we had to handle a large sample size, which 
tends to result in a lower variance with respect to the mean 
value, what is called underdispersion and could lead to 
biased, smaller SEs. Therefore, we used the residual devi-
ance as scale parameter.
We estimated MRRs separately for both sexes and over 
5- year age groups for adults in the age range 30–95 years 
and older. We also calculated age- adjusted MRRs strati-
fied by sex based on the 5- year age groups.
Figure 2 Age- specific mortality rates per 100 000 persons 
stratified by sex for the year 2014 as obtained from official 
cause of death statistics (Destatis) and claims data (Datrav). 
The blue line indicates results from official statistics; the 
green line indicates results from the DaTraV dataset. DaTraV, 
Data Transparency Regulation Act.
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In order to assess the impact of modified case defini-
tions on the study results, we conducted two sensitivity 
analyses calculating the age- adjusted MRRs for men and 
women as described above.
RESULTS
Description of the study population
Compared with men, women were over- represented in 
the population without diabetes, whereas proportions 
of men and women were similar in the population with 
diabetes (table 1). Accordingly, the diabetes prevalence 
among women (12.8%) was lower than in men (14.9%). 
As expected, the population with diabetes had a higher 
mean age compared with the population without diabetes. 
On average, women were older than men among persons 
with and without diabetes. In terms of absolute numbers, 
more women than men died in 2014 in the population 
with and without diabetes. However, age- specific and 
age- standardised mortality rates per 1000 persons were 
consistently higher among men than women in both 
populations. In both sexes, mortality rates per 1000 
persons were markedly higher among individuals with 
diabetes than without diabetes (table 1).
Main analysis
MRR estimates, in association with diagnosed diabetes 
as obtained from Poisson regression, are depicted in 
figure 3. For both sexes, the age- specific MRR estimates 
decreased with increasing chronological age from 6.76 
among women and 6.87 among men in the youngest 
age group to 3.12 among women and 2.46 among men 
aged 50–54 years to 1.13 among women and 1.11 among 
men aged 95 years and older. Except for persons younger 
than 40 years of age, MRR estimates in association with 
diabetes were higher among women than men. In partic-
ular, among persons 50–79 years, the MRR was between 
1.26 and 1.12 significantly times higher among women 
than men.
Overall adjusted MRR estimates were comparable for 
women and men (1.52 vs 1.56). Constraining our analysis 
to persons below 90 years of age reversed the overall age- 
adjusted MRRs regarding sex with still comparable esti-
mates of 1.66 for women and 1.61 for men.
Sensitivity analyses
An excess risk of death in association with diabetes among 
men and women was confirmed in two sensitivity anal-
yses applying less stringent case definitions for diabetes 
(table 2).
Compared with the main analysis, where the case defini-
tion for diabetes required documentation of a confirmed 
diabetes diagnosis in at least two- quarters of the year 2013 
for outpatient data or one inpatient diagnosis of diabetes 
in 2013, the first case definition in table 2 additionally 
includes persons with only one confirmed outpatient 
diagnosis of diabetes in 2013. This means that about 
0.5 million persons were added to the population with 
Figure 3 MRRs for persons with diabetes compared with 
persons without diabetes by sex and age groups. Overall 
estimates are adjusted using all displayed age groups. MRR, 
mortality rate ratio.
Table 1 Descriptive characteristics of the study population 
by diabetes status and sex (DaTraV, age ≥30 years)
No diabetes Diabetes
Women Men Women Men
Population size 
in million (2013)
22.5 18.3 3.3 3.2
Proportion (%) 
2013
55.1 44.9 50.8 49.2
Mean age in 
years 2013
55.9 53.6 71.5 67.9
Number of 
deaths 2014
254 408 220 305 148 491 140 024
Mortality rate per 
1000 persons*
12.00 12.74 19.96 21.91
Mortality rate per 1000 persons across age groups*
  30–34 years 0.30 0.62 2.03 4.26
  35–39 years 0.45 0.87 1.86 4.38
  40–44 years 0.77 1.40 3.75 5.31
  45–49 years 1.29 2.34 4.62 7.64
  50–54 years 2.23 4.13 6.95 10.18
  55–59 years 3.41 6.73 9.19 14.55
  60–64 years 5.21 10.71 11.18 19.84
  65–69 years 7.80 15.44 15.42 25.84
  70–74 years 11.63 22.35 22.56 38.24
  75–79 years 19.15 33.64 35.17 55.34
  80–84 years 40.02 62.14 62.97 89.99
  85–89 years 83.06 111.42 113.91 144.18
  90–94 years 157.24 191.04 194.06 229.21
  95 years and 
older
270.33 303.74 304.13 336.90
*Age standardised to the German population 2013 using all 
displayed age groups.
DaTraV, Data Transparency Regulation Act.
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diabetes and at the same time removed from the popula-
tion without diabetes compared with the numbers used 
for the main analysis as shown in figure 1. Results of this 
sensitivity analysis were similar to those of the main anal-
ysis, with only slightly lower overall MRR estimates of 1.51 
among women and 1.55 among men. In contrast, mark-
edly attenuated overall MRR estimates were obtained in 
the second sensitivity analysis, where the case definition 
for diabetes was based on the documentation of only one 
confirmed outpatient diagnosis. Still, the age- adjusted 
MRRs resulting from this case definition showed a signifi-
cantly nearly 20% higher risk of death in men and women 
with diagnosed diabetes compared with those without 
diagnosed diabetes (table 2).
DISCUSSION
Main findings
To the best of our knowledge, we present for the first 
time deeply age- stratified MRR estimates in association 
with diagnosed diabetes among men and women 30 
years of age and older in Germany based on SHI claims 
data covering about 90% of the population. Overall, 
men and women with diabetes had an about 50% higher 
age- adjusted risk of death compared with adults without 
diabetes. Across strata of increasing age, the diabetes- 
related MRRs considerably decreased with slightly higher 
estimates among women than men in the population 
aged 40–80 years. Results persisted in sensitivity analyses 
applying modified case definitions for diabetes, with the 
exception of markedly reduced although still significantly 
higher diabetes- related risk of death based on the least 
stringent case definition for diabetes requiring only one 
outpatient diagnosis for diabetes throughout the year 
2013.
Our findings regarding age- related decreases in 
diabetes- related MRRs partly agree with results from two 
previous nationwide studies in Germany.10 17 A population- 
based cohort study based on 12- year- mortality follow- up of 
adults participating in the German National Health Inter-
view and Examination Survey 1998 reported decreasing 
age- specific diabetes- related MRRs in both sexes as well 
as overall age- adjusted MRR estimates of similar magni-
tude as in the present study.17 In this previous analysis 
no sex differences in MRRs from all causes in association 
with diagnosed type 2 diabetes were observed, although 
significantly detection of a sex differential may have been 
precluded by a limited number of deaths among adults 
with diabetes. Tönnies et al calculated type 2 diabetes- 
related MRR applying an illness- death model, with esti-
mates on diabetes prevalence and incidence derived from 
SHI claims data and mortality rates of the general popula-
tion from official death statistics. These authors reported 
age- related decreases in MRRs, but considerably higher 
overall age- adjusted MRR estimates, with higher estimates 
among women than men (3.0 vs 2.3).10 For comparison 
with this previous study which focused on the population 
65–90 years of age in Germany, we limited our analyses 
to the population aged 65–90 years and found no differ-
ences in MRRs between women and men (1.47 vs 1.48). 
The study by Jacobs et al18 calculated, on the basis of the 
DaTraV dataset as well, the excessive deaths for women 
and men over 40 years of age in Germany. As no such data 
were available for Germany at that time, Jacobs et al took 
the mortality rates from the Danish National Diabetes 
Register. The study found absolute excess deaths related 
to diabetes of 81 703 for women and 92 924 for men. In 
contrast, using the same methods but the estimated MRRs 
for Germany in our study, we found considerably fewer 
absolute excess deaths of 49 136 for women and 53 872 
for men.
Consistent with our results, nationwide studies in several 
other countries based on diabetes registers or diabetes 
surveillance systems have reported a higher diabetes- 
related risk of all- cause mortality compared with general 
population or population- based controls but differ in 
magnitude.4–6 8 19
The Swedish National Diabetes Register and the Austra-
lian diabetes surveillance showed that the excess risk 
of death in association with diagnosed type 2 diabetes 
declined with increasing chronological age.6 8 Although 
the present study could not differentiate by type of 
diabetes, these results are in line with our findings, since 
type 2 diabetes accounts for the vast majority of diabetes 
cases among older adults. The age- related decline in 
diabetes- related excess risk of all- cause mortality might 
be due to the different onsets of diabetes on the life 
span and the associated disease duration. It may reflect 
increases in competing risk of death in older age groups 
Table 2 Sensitivity analyses applying modified diabetes case definitions: number of persons by diabetes status and age- 












Sensitivity analysis 1* 22.3/3.6 1.51 (1.51 to 1.51) 18.1/3.4 1.55 (1.55 to 1.55)
Sensitivity analysis 2† 22.3/0.25 1.19 (1.18 to 1.20) 18.1/0.21 1.20 (1.19 to 1.21)
*Documentation of at least one outpatient (confirmed) or inpatient diagnosis of diabetes in 2013.
†Documentation of only one outpatient (confirmed) diagnosis of diabetes in 2013. Deviations from figures in figure 1 are due to rounding.
DaTraV, Data Transparency Regulation Act.
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as well as survival disadvantage in association with 
increased diabetes duration. In addition, the number of 
severe comorbidities in people with and without diabetes 
converges with increasing age.
With regard to sex differences in diabetes- related rela-
tive risk or excess risk of all- cause mortality, previous studies 
from other countries showed conflicting findings.4 5 8 Our 
age- specific estimates of diabetes- related MRRs showed 
higher risk estimates among women than among men for 
persons aged 50–79 years. This higher risk among women 
declined with increasing age and diminished in the oldest 
age groups. This consistent pattern is comparable with a 
study from Australia for 2004–2010 which showed higher 
standardised mortality ratios (SMRs) in women than in 
men especially for persons aged 50–79 years and very 
similar SMRs for women and men aged 80 years or older 
(1.03 and 0.98).8 A recently conducted systematic review 
and meta- analysis including 49 studies with 86 prospective 
cohorts showed a combined MRR of 1.93 for women and 
1.74 for men with a pooled women- to- men ratio of rela-
tive risks (RRR) of 1.13.7 However estimates across studies 
ranged from 1.24 to 3.67 in women and from 1.32 to 3.13 
in men, pooled women- to- men RRR varied from 0.64 to 
1.74.7 Overall, differences in study results regarding a 
sex differential in excess risk of diabetes- related all- cause 
mortality might, at least in part, be explained by differ-
ences in the age range, underestimation of older people, 
time of follow- up and applied methods for risk estimation.
Prospective population- based studies are needed to 
obtain a deeper insight into the role of sex difference 
in diabetes- related mortality risks by taking relevant 
risk factors such as lifestyle behaviour, adherence to 
prescribed therapy and comorbidities into account.
Practical implications
Our findings confirm that diagnosed diabetes in Germany 
is still associated with a significantly elevated, several 
times higher risk of death among men and women, in 
particular in younger and middle- aged persons. This 
emphasises the need for effective primary and secondary 
prevention. Further improvements in the early detection 
of diabetes, particularly in younger ages, alongside with 
evidence- based treatments, could contribute to a reduc-
tion in excess mortality.
Our results open the perspective to close an important 
gap in diabetes surveillance in Germany, as the SHI 
claims dataset appears to be suitable for close monitoring 
of diabetes- related excess risk of death, which is a key 
indicator in the national diabetes surveillance system. 
In addition, the dataset will permit calculation of closely 
related indicators, including the absolute number of 
deaths in association with diabetes, and composite indi-
cators of disease burden, including healthy life years and 
the number of years lost in association with diabetes.20 
Thus, including SHI claims dataset will harness the poten-
tial for improved health information systems as a basis for 
the surveillance of diabetes and other non- communicable 
diseases (NCDs).
Strengths and limitations
The main strength of our analysis is the completeness of 
the dataset, since about 90% of the German population 
is covered by SHI. Mortality rates derived from the SHI 
claims dataset showed good agreement with data from 
official death statistics, which underlines the potential for 
generalisation of our results. Our findings from sensitivity 
analyses support the validity of the data. We consistently 
showed an excess risk of all- cause mortality in association 
with diagnosed diabetes based on varying case definitions 
for diabetes.
Taken together, our results demonstrate that the DaTraV 
dataset could essentially contribute to close current gaps 
in diabetes surveillance with an overall good documen-
tation quality of diabetes and the advantage to consider 
inpatient as well as outpatient data for case definition.
A great disadvantage of routine datasets based solely 
on documented diagnoses is that no information about 
undiagnosed morbidity can be drawn. National surveys 
with an additional HbA1c measurement in blood samples 
of participants show a relevant proportion of undiag-
nosed diabetes. Although this proportion has decreased 
over time, it is still relatively high21 and at the same time 
is related to a slightly higher excess mortality than diag-
nosed diabetes.17 22 For this reason the current routine 
data analysis is likely to underestimate the excess mortality 
in diabetes. In general, another limitation of routine data 
is that these data cannot identify the ethnicity of individ-
uals. An ethnic risk profile is being discussed for diabetes 
in particular.23
There are a number of limitations which arise from the 
specific construction of the DaTraV dataset, which orig-
inally served economic but not research purposes. We 
had to determine cases of diabetes in the data in 2013 
only, in order to identify persons who died in 2014 among 
persons with and without diabetes. This implies that those 
who died with newly documented diabetes in 2014 are 
not detectable in the data as diabetes cases and hence 
will be counted as persons without diabetes. We cannot 
exclude that this also contributed to an underestimation 
of diabetes- related excess mortality. Since diabetes is a 
chronic disease, and long- term complications account for 
the majority of diabetes- related deaths, we assume that 
this had only little impact on our results. The planned 
revision of the Data Transparency Regulations in Germany 
could help to overcome current shortcomings.
Furthermore, the currently missing stratification of the 
dataset according to geographical region and social status 
or social deprivation should be possible in the future, 
hence we will be able to analyse and compare mortality 
trends within Germany as well as at a national level with 
other countries.
The present study included adults 30 years of age and 
older, and type 2 diabetes is likely to account for most 
cases of documented diabetes. Nevertheless, it will be 
important to overcome current limitations to differentiate 
between major types of diabetes in claims data. The main 
problem is the frequent coding of an unspecific diabetes 
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(ICD-10: E14) or even diagnoses that are mutually exclu-
sive (E10 and E11) in the data.24 A recent analysis of 
the dataset used here has demonstrated that including 
information on medication may improve assignment of 
unspecific diabetes codes to type 2 diabetes.25 Among 
children and adolescents, type 1 diabetes is the predom-
inant type of diabetes. As insulin treatment is required 
here, documented insulin use is an essential part of the 
case definition for type 1 diabetes, and also helps to clarify 
diabetes definition.26
CONCLUSIONS
Diabetes- related risk of death is a key indicator for moni-
toring diabetes epidemiology and quality of diabetes 
care. Establishing sustainable time trends for this indi-
cator as part of the national diabetes surveillance system 
in Germany is of great need, but was so far precluded by 
the lack of a valid and timely accessible dataset. Results 
of the present study demonstrate that analysis of SHI 
claims data may provide a solution in closing this infor-
mation gap. Further research is needed to analyse and to 
improve the quality of the data, in particular with regard 
to case definitions. In this case, the SHI claims data could 
also serve to calculate and monitor the absolute number 
of diabetes- related deaths as well as composite indica-
tors of disease burden, such as diabetes- related healthy 
life years and years of life lost. Stratification of SHI 
claims data according to geographical region and social 
status or social deprivation will be possible in the future, 
hence we will be able to analyse and compare diabetes- 
related mortality trends not only within Germany but also 
with international developments.3 This will strengthen 
surveillance activities for the prevention and control of 
diabetes and other major NCDs at a national level and 
also enhance international collaboration in diabetes and 
NCD surveillance and burden of disease estimates.
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